CTNM vs DFTX
CTNM: A clinical-stage biopharmaceutical company developing small-molecule therapies targeting neuroimmune and inflammatory indications, with lead programs PIPE-791 for idiopathic pulmonary fibrosis and chronic pain, and PIPE-307 for depression and multiple sclerosis. DFTX: Definium is applying scientific rigor to psychedelics and empathogens to develop FDA-breakthrough-designated treatments for anxiety, depression, PTSD, and autism.
Side-by-side fundamentals
| Metric | CTNM | DFTX | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $14.73 | $43.67 | |
| Market cap as of 2026-07-23 | $518M | $5.8B | |
| PEG as of 2026-07-23 | -6.25 | -0.13 | CTNM lower |
| Net margin as of 2026-07-23 | +45.4% | n/a | |
| Operating margin as of 2026-07-23 | +32.1% | n/a | |
| ROE as of 2026-07-23 | -27.1% | -102.5% | CTNM higher |
| ROA as of 2026-07-23 | -25.6% | -70.7% | CTNM higher |
| Debt / equity as of 2026-07-23 | 0.00 | 0.15 | CTNM lower |
| Beta as of 2026-07-23 | 0.62 | 2.29 | |
| 1-year return as of 2026-07-22 close | +146.0% | +353.1% | DFTX higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.